LOGO.png
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
August 09, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
August 05, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
August 02, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
July 15, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
July 08, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
June 15, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
June 11, 2021 07:00 ET | Autolus Therapeutics plc
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
LOGO.png
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
May 25, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
LOGO.png
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
May 21, 2021 07:00 ET | Autolus Therapeutics plc
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...
LOGO.png
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress
May 12, 2021 10:00 ET | Autolus Therapeutics plc
AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 ...